Tennessee Valley Asset Management Partners Makes New $49,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Tennessee Valley Asset Management Partners purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 611 shares of the biopharmaceutical company’s stock, valued at approximately $49,000.

Several other large investors also recently bought and sold shares of the stock. Perigon Wealth Management LLC increased its holdings in Gilead Sciences by 10.4% during the 4th quarter. Perigon Wealth Management LLC now owns 40,668 shares of the biopharmaceutical company’s stock worth $3,294,000 after purchasing an additional 3,832 shares during the period. Valeo Financial Advisors LLC increased its holdings in Gilead Sciences by 7.1% during the 4th quarter. Valeo Financial Advisors LLC now owns 7,363 shares of the biopharmaceutical company’s stock worth $596,000 after purchasing an additional 491 shares during the period. Sapient Capital LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $324,000. Round Rock Advisors LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $239,000. Finally, Janiczek Wealth Management LLC boosted its position in shares of Gilead Sciences by 7.2% during the 4th quarter. Janiczek Wealth Management LLC now owns 6,115 shares of the biopharmaceutical company’s stock worth $495,000 after acquiring an additional 411 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several analyst reports. Royal Bank of Canada lowered their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research report on Friday, April 19th. Cantor Fitzgerald lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. UBS Group lowered their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Finally, StockNews.com cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 19th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $84.71.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Up 0.1 %

Gilead Sciences stock opened at $67.03 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $65.90 and a twelve month high of $87.86. The stock has a 50 day moving average of $71.68 and a two-hundred day moving average of $76.46. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The stock has a market capitalization of $83.46 billion, a price-to-earnings ratio of 14.90, a PEG ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same period in the previous year, the business posted $1.67 earnings per share. The firm’s revenue was down 3.7% compared to the same quarter last year. As a group, research analysts expect that Gilead Sciences, Inc. will post 6.55 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.59%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.